<DOC>
	<DOCNO>NCT00002335</DOCNO>
	<brief_summary>To assess safety pharmacokinetics single oral dos 524W91 administer HIV-infected patient . To determine effect food bioavailability 524W91 .</brief_summary>
	<brief_title>The Safety Effectiveness 524W91</brief_title>
	<detailed_description>Patients randomize receive six single escalate dos 524W91 placebo , dose separate least 6-day washout interval . In time 2 dos , effect food pharmacokinetics investigate , one dose administer conjunction high-fat meal one dose administer fasted state .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<criteria>Inclusion Criteria Patients must : Documented HIV infection . CD4 count &gt; = 200 cells/mm3 . No active opportunistic infection . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Malignancy condition would confound study assessment interfere ability complete study . Malabsorption syndrome gastrointestinal dysfunction might interfere gastrointestinal absorption . Concurrent Medication : Excluded day dose : Antiretrovirals . Any prescription overthecounter medication . Alcoholic beverage . Coffee , tea , xanthinecontaining beverage food . Patients follow prior condition exclude : History hepatitis , pancreatitis , cardiomyopathy within past 5 year . Prior Medication : Excluded : Antiretrovirals within 24 hour prior dose . Any prescription overthecounter medication within 48 hour prior dose . Alcoholic beverages within 48 hour prior dose . Current alcohol illicit drug use may affect patient compliance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 1996</verification_date>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Antiviral Agents</keyword>
</DOC>